---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-24-000040"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:28:46.511842+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rallybio announces J&J collaboration with $0.5M upfront and $6.6M equity for FNAIT

## Summary
- Collaboration with J&J: Rallybio receives $0.5M upfront, up to $3.7M milestones for FNAIT data sharing and awareness.
- J&J affiliate JJDC invests $6.6M via purchase of 3.6M shares in private placement at ~$1.82/share.
- Rallybio's RLYB212 (preventative for non-alloimmunized) and J&J's nipocalimab (for alloimmunized) target FNAIT; Phase 2 for RLYB212 expected H2 2024.
- JJDC locked up from selling shares for 180 days; collaboration agreement expires April 9, 2026.

## SEC filing metadata
- accession: 0001739410-24-000040
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/0001739410-24-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/rlyb-20240409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-24-000040
- JSON: https://secwatch.observer/filing/0001739410-24-000040.json
- Plain text: https://secwatch.observer/filing/0001739410-24-000040.txt

## Key facts
- Material Agreements
  Rallybio Corp entered into Collaboration Agreement with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. valued at $0.5 million (effective 2024-04-09).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc.
  - Value: $0.5 million
  - Effective: 2024-04-09
  source text: On April 9, 2024, Rallybio Corporation (the “Company”), through its subsidiary Rallybio IPA, LLC, entered into a collaboration agreement (the “Collaboration Agreement”) with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. (“J&J”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/0001739410-24-000040-index.htm
- Material Agreements
  Rallybio Corp entered into Securities Purchase Agreement with Johnson & Johnson Innovation – JJDC, Inc. valued at approximately $6.6 million (effective 2024-04-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Johnson & Johnson Innovation – JJDC, Inc.
  - Value: approximately $6.6 million
  - Effective: 2024-04-10
  source text: On April 10, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Johnson & Johnson Innovation – JJDC, Inc., a Delaware corporation (the “Purchaser”), pursuant to which the Company sold to the Purchaser, in an unregistered offering (the “Offering”), shares of common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/0001739410-24-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.